Investors have been keeping a sharp eye on Bristol Myers as its stock has lagged behind peers recently. Bristol Myers’ stock ...

Bristol-Myers Squibb is testing MORAb-202 in a Phase 2 trial to challenge traditional chemotherapy for platinum-resistant ...

Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medicationsTARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals ...

Patient-Assistance Programs: Assessment of and Use by Safety-Net Clinics Kathryn Saenz Duke; Kristiana Raube; Helene Levens Lipton Disclosures Am J Health Syst Pharm. 2005;62 (7):726-731.

Patient-Assistance Programs: Assessment of and Use by Safety-Net Clinics Kathryn Saenz Duke; Kristiana Raube; Helene Levens Lipton Disclosures Am J Health Syst Pharm. 2005;62 (7):726-731.

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company.

Cutaneous Lupus Erythematosus Market Research Report 2025-2035, Competitive Analysis of Biogen, Bristol-Myers Squibb, Sanofi, AstraZeneca, Gilead Sciences, and Kyowa Kirin - ResearchAndMarkets.com ...

Bristol Myers Squibb (BMY) closed at $48.66 in the latest trading session, marking a -2.19% move from the prior day. This change lagged the S&P 500's 0.94% gain on the day. At the same time, the ...

Innovative Agents Highlight Growth of Targeted Protein Degradation Platform and BMS’ Leadership in Innovative Cancer Therapies PRINCETON, NJ, USA I June 12, 2025 I Bristol Myers Squibb (NYSE: BMY) ...

Bristol Myers CEO stays bullish on Cobenfy despite trial flop, signs of slowing momentum By Angus Liu Jun 12, 2025 12:43pm Bristol Myers Squibb Cobenfy Chris Boerner drug launch ...